Pharmacoadherence: An Opportunity for Digital Health to Inform the Third Dimension of Pharmacotherapy for Diabetes

J Diabetes Sci Technol. 2021 Jan;15(1):177-183. doi: 10.1177/1932296820973185. Epub 2020 Dec 8.

Abstract

The basis of pharmacotherapy requires knowledge of two properties of a drug: pharmacokinetics (PK) and pharmacodynamics (PD). In the era of precision medicine, there is growing interest in determining between-individual variations in PK and PD. While these two dimensions of pharmacotherapy are key foci of investigation, a third property is also emerging as a critical factor in understanding how a drug affects an individual. This third property of a drug is known as phamacoadherence (PA). There can be wide variation in PA among people with diabetes, whether they are using oral or injectable medications. The use of new digital health interventions and telehealth communication tools, such as smart insulin pens, is now creating opportunities for health care professionals to have a more complete understanding of the PA of drugs, which allows for more personalized prescribing practices.

Keywords: diabetes; digital health; missed insulin; pharmacoadherence.

MeSH terms

  • Diabetes Mellitus* / drug therapy
  • Humans
  • Insulin Infusion Systems
  • Precision Medicine
  • Telemedicine*